You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ACCUHALER/DISKUS

Showing 1 - 25 of 139
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Asthma, COPD Trial in San Antonio (MGR001, Advair® Diskus®, Seretide™ Accuhaler™)

Completed
  • Asthma
  • COPD
  • San Antonio, Texas
    Worldwide Clinical Trials Early Phase Services
Feb 22, 2022

Asthma Trial in Canada, United States (Fluticasone furoate/ Vilanterol 100 mcg/25 mcg, Fluticasone propionate 250 mcg, Placebo

Completed
Has Results
  • Asthma
  • Fluticasone furoate/ Vilanterol 100 mcg/25 mcg
  • +3 more
  • Huntington Beach, California
  • +15 more
Jul 5, 2019

Asthma Trial in Athens (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals, ADVAIR

Not yet recruiting
  • Asthma
  • Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals
  • +2 more
  • Athens, Greece
    BECRO Ltd.
Jan 20, 2023

Asthma Trial in United States (MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed

Completed
Has Results
  • Asthma
  • MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
  • +2 more
  • Birmingham, Alabama
  • +100 more
Feb 22, 2022

Asthma Trial (RP - TA)

Completed
  • Asthma
  • RP - TA
  • (no location specified)
Jul 12, 2022

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (FF/VI 100/25 Inhalation Powder NDPI, Fluticasone

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • FF/VI 100/25 Inhalation Powder NDPI
  • +4 more
  • Clearwater, Florida
  • +63 more
Apr 30, 2018

COPD Trial in Antalya (Salmeterol/Fluticasone Capsair®, Salmeterol/Fluticasone Diskus®)

Terminated
  • COPD
  • Salmeterol/Fluticasone Capsair®
  • Salmeterol/Fluticasone Diskus®
  • Antalya, Turkey
  • +1 more
May 16, 2022

COPD (COPD) Trial in Bordeaux (Seretide® Diskus® 500/550 µg, Ultibro® Breezhaler® 110/50 µg, Spiriva® Respimat® 2,5 µg)

Completed
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Seretide® Diskus® 500/550 μg
  • +2 more
  • Bordeaux, France
    CIC-P - Centre François Magendie - G3 - Hôpital Haut-Lévêque
Feb 8, 2022

Asthma Trial in Worldwide (Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler, Placebo inhalation powders via ELLIPTA

Completed
Has Results
  • Asthma
  • Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler
  • +4 more
  • Huntington Beach, California
  • +178 more
Aug 2, 2018

Pooled Analysis FP_SX_250_50

Completed
  • Asthma
  • Larissa, Thessaly, Greece
    BECRO Clinical Facility
Mar 5, 2021

Asthma Trial in Czechia (Elpenhaler active - Diskus )

Completed
  • Asthma
  • Elpenhaler active - Diskus placebo
  • Karlovy Vary, Drahovice, Czechia
  • +4 more
Apr 8, 2021

Asthma Trial in Denver (Qvar, Flovent Diskus)

Terminated
  • Asthma
  • Denver, Colorado
    National Jewish Medical and Research Center
Nov 19, 2021

Asthma Trial in Raleigh, Edmond, San Antonio (Treatment A: Fp MDPI, Treatment B: FS MDPI, Treatment C Flovent)

Completed
  • Asthma
  • Treatment A: Fp MDPI
  • +3 more
  • Raleigh, North Carolina
  • +2 more
Nov 6, 2021

Asthma Trial in Athens (Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals, FLOVENT DISKUS®

Recruiting
  • Asthma
  • Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals
  • +2 more
  • Athens, Greece
    BECRO Ltd.
Jan 19, 2021

Pulmonary Disease, Chronic Obstructive Trial in Canada, Denmark (GSK2269557, Placebo, DISKUS)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • Vancouver, British Columbia, Canada
  • +5 more
Aug 12, 2021

Asthma, Bioequivalence Trial in Larissa (Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent

Active, not recruiting
  • Asthma
  • Bioequivalence
  • Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
  • FLOVENT DISKUS
  • Larissa, Thessaly, Greece
    BECRO Clinical Facility
May 25, 2022

Bioequivalence, Asthma Trial in Larissa (Test, Reference)

Active, not recruiting
  • Bioequivalence
  • Asthma
  • Larissa, Thessaly, Greece
    BECRO Clinical Facility
Oct 19, 2021

Pulmonary Disease, Chronic Obstructive Trial in United States (ELLIPTA DPI, DISKUS DPI, HandiHaler DPI)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • ELLIPTA placebo DPI
  • +3 more
  • Orlando, Florida
  • +17 more
Jun 26, 2020

Asthma Trial in Athens (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals, ADVAIR

Completed
  • Asthma
  • Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals
  • +2 more
  • Athens, Greece
    BECRO Ltd.
Jul 5, 2020

Error Rates Between ELLIPTA® Dry Powder Inhaler and Other DPIs

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • Relvar ELLIPTA
  • +6 more
  • Beek En Donk, Netherlands
  • +12 more
Oct 6, 2020

Asthma, Bioequivalence Trial in Larissa (Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent

Recruiting
  • Asthma
  • Bioequivalence
  • Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
  • FLOVENT DISKUS
  • Larissa, Thessaly, Greece
    BECRO Clinical Facility
Aug 19, 2021

Asthma Trial in Worldwide (FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg)

Completed
Has Results
  • Asthma
  • FF/UMEC/VI (100/31.25/25) mcg
  • +10 more
  • Birmingham, Alabama
  • +408 more
Feb 26, 2021

Bioequivalence, Asthma Trial in Larissa (Test, Reference)

Active, not recruiting
  • Bioequivalence
  • Asthma
  • Larissa, Thessaly, Greece
    BECRO Clinical Facility
Apr 18, 2021

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (UMEC/VI 62.5/25 mcg via ELLIPTA, UMEC 62.5 mcg via ELLIPTA,

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • UMEC/VI 62.5/25 mcg via ELLIPTA
  • +4 more
  • Phoenix, Arizona
  • +212 more
Mar 2, 2020

Bioequivalence Trial in Larissa (Test Product, Reference Product)

Completed
  • Bioequivalence
  • Test Product
  • Reference Product
  • Larissa, Thessaly, Greece
    BECRO Clinical Facility
Mar 8, 2021